Insights

Accelerated API manufacturing by combining early-stage and late-stage process development

icons/content-types/white paper white paper

Process Development Small Molecules

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under an orphan or fast-track indication, the traditional approach of linear development stages can be counterproductive—not to mention expensive—due to investing resources in perfecting a process prior to early clinical phase success. Addressing some of the aspects of late-stage process development during the initial process development can help save valuable time following phase 1 clinical studies

Download our white paper for insights on:

  • Seven considerations when combining early- and late-stage process development for fast-track drugs
  • Late-stage development to commercialization
  • When it comes to speed, Integrated process development counts

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/white paper white paper

FDA's Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER's Rating System?

Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...

icons/content-types/white paper white paper

Bispecific antibodies unleashed

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising ther...